Polaryx Therapeutics, Inc. (PLYX) Revenue, Earnings & Financial Statements
$1.60NASDAQ: PLYXMarket Cap $79.75M
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Polaryx Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $9.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Polaryx Therapeutics, Inc.: net profit was positive in 0 of 3 reported years; the most recent year shows a net loss of $9.0M.
Income Statement — 3 Years (USD millions)
Metric
2023
2024
2025
Revenue
$0
$0
$0
Operating Expenses
$4.0M
$4.0M
$8.0M
Operating Profit
−$4.0M
−$4.0M
−$8.0M
Other Income
$0
−$26.0M
−$1.0M
Interest
$0
$0
$0
Depreciation
$0
$0
$0
Profit Before Tax
−$4.0M
−$30.0M
−$9.0M
Tax rate (%)
0.0%
0.0%
0.0%
Net Profit
−$4.0M
−$30.0M
−$9.0M
EPS
−$0.02
−$0.16
−$0.19
Quarterly Results — Last 11 Quarters (USD millions)
Metric
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$2.0M
$1.0M
$1.0M
$1.0M
$5.0M
$1.0M
$1.0M
$1.0M
$2.0M
$1.0M
$3.0M
Operating Profit
−$2.0M
−$1.0M
−$1.0M
−$1.0M
−$5.0M
−$1.0M
−$1.0M
−$1.0M
−$2.0M
−$1.0M
−$3.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$28.0M
−$1.0M
−$1.0M
−$1.0M
−$5.0M
−$1.0M
−$1.0M
−$1.0M
−$3.0M
−$1.0M
−$3.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$28.0M
−$1.0M
−$1.0M
−$1.0M
−$5.0M
−$1.0M
−$1.0M
−$1.0M
−$3.0M
−$1.0M
−$3.0M
EPS
−$1.13
−$0.04
$0.00
$0.00
−$0.03
−$0.01
−$0.01
−$0.03
−$0.05
−$0.03
−$0.07
Over the 3 years reported for Polaryx Therapeutics, Inc., cash stood at $5.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 5.00 times.
Balance Sheet — 3 Years (USD millions)
Metric
2023
2024
2025
Total Assets
$2.0M
$5.0M
$5.0M
Current Assets
$2.0M
$5.0M
$5.0M
Cash
$0
$5.0M
$5.0M
Inventory
$0
$0
$0
Receivables
$0
$0
$0
Fixed Assets
$0
$0
$0
Capital Work in Progress
$0
$0
$0
Investments
$0
$0
$0
Other Assets
$0
$0
$0
Total Liabilities
$1.0M
$0
$1.0M
Current Liabilities
$1.0M
$0
$1.0M
Borrowings
$0
$0
$0
Other Liabilities
$1.0M
$0
$1.0M
Equity
$0
$0
$0
Reserves
$1.0M
$5.0M
$5.0M
For Polaryx Therapeutics, Inc., operating cash flow was positive in 0 of 3 reported years; free cash flow in the latest year was negative at $4.0M; free cash flow was positive in 0 of 3 years.
Cash Flow Statement — 3 Years (USD millions)
Metric
2023
2024
2025
Operating Cash Flow
$0
−$3.0M
−$4.0M
Investing Cash Flow
$0
$0
$0
Financing Cash Flow
$0
$0
$0
Net Cash Flow
$0
$5.0M
$1.0M
Free Cash Flow
$0
−$3.0M
−$4.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.11
EV / EBITDA
-9.12
FCF Yield
-9.09%
Quick Ratio
8.62
Interest Coverage
—
Return 1Y
—
Return 3Y
—
Return 5Y
—
Polaryx Therapeutics, Inc. (PLYX) financials — frequently asked questions
What is Polaryx Therapeutics, Inc.'s annual revenue?
Polaryx Therapeutics, Inc. (PLYX) reported annual revenue of $0 in its most recent fiscal year.
What is Polaryx Therapeutics, Inc.'s net profit?
Polaryx Therapeutics, Inc. (PLYX) reported a net loss of $9.0M in its most recent fiscal year.
What is PLYX EV/EBITDA?
Polaryx Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -9.12. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks